))
Esketamine nasal spray for treatment resistant depression - Ep 47
Manage episode 322452177 series 3286334
Content provided by ACCPpostgrads. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by ACCPpostgrads or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Dr. Autumn Walkerly provides an overview of Spravato (esketamine) nasal spray for treatment resistant depression.
References:
Gaynes BN, Lux L, Gartlehner G, et al. Defining treatment-resistant depression. Depress Anxiety. 2020;37(2):134-45.
Irwin MN, VandenBerg A. Retracing our steps to understand ketamine in depression: A focused review of hypothesized mechanisms of action. Ment Health Clin. 2021;11(3):200-10.
Rush AJ, Trivedi MH, Wisniewski SR, et al. "Acute and longer-term outcomes in depressed outpatient requiring one or several treatment steps: A STAR*D report". Am J Psychiatry. 2006. 163(11):1905-17.
Daly EJ, Trivedi MH, Janik A, et al. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2019;76(9):893-903.
Fu DJ, Ionescu DF, Li X, et al. Esketamine nasal spray for rapid reduction of major depressive disorder symptoms in patients who have active suicidal ideation with intent: double-blind, randomized study (ASPIRE I). J Clin Psychiatry. 2020;81(3):19m13191.
Popova V, Daly EJ, Trivedi M, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry. 2019;176(6):428-38.
67 episodes
Share
